![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Article |
|---|---|
| Title: | Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age |
| Creators Name: | Nowek, K., Sun, S.M., Dijkstra, M.K., Bullinger, L., Döhner, H., Erkeland, S.J., Löwenberg, B. and Jongen-Lavrencic, M. |
| Abstract: | In double-stranded miRNA/miRNA* duplexes, one of the strands represents an active miRNA, whereas another, known as a passenger strand (miRNA*), is typically degraded. MiR-9* is not detectable in normal myeloid cells. Here we show that miR-9* is expressed in 59% of acute myeloid leukemia (AML) cases and we investigate its clinical impact in 567 adults with de novo AML (age⩽60 years). AML cases with detectable miR-9* included a lower percentage of cases with favorable risk (P<0.001) as compared with those with no detectable miR-9*. High levels of miR-9* expression independently predicted for higher complete remission (odds ratio=1.28, P=0.013) and better event-free survival (EFS) (hazard ratio (HR)=0.86, P=0.001), relapse-free survival (RFS) (HR=0.84, P=0.008) and overall survival (OS) (HR=0.86, P=0.002). Among the subgroup of adverse risk patients, high miR-9* expressers had strikingly longer median survival than low miR-9* expressers (EFS: 16 vs 5 months, P=0.020; RFS: 12 vs 4, P=0.060; OS: 23 vs 8, P=0.021). Comparative transcriptome analysis suggests that miR-9* regulates genes involved in leukemogenesis, for example, MN1 and MLLT3. This is the first report showing that an miRNA* has prognostic value in AML. |
| Keywords: | MicroRNAs, Middle Aged, Myeloid Acute Leukemia |
| Source: | Leukemia |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Volume: | 30 |
| Number: | 2 |
| Page Range: | 303-9 |
| Date: | February 2016 |
| Official Publication: | https://doi.org/10.1038/leu.2015.282 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
